Business Description
Mesoblast is an Australian biotech company founded in 2004 that develops cell-based therapies to treat serious conditions such as heart failure, inflammatory diseases, and chronic back pain. Their work centers on a proprietary technology built around a specific type of stem cell, which forms the basis of several treatments currently in late-stage clinical trials. The company operates across multiple countries and works with established partners including Tasly Pharmaceutical Group, JCR Pharmaceuticals, and Grünenthal to bring these therapies to patients around the world.
